RxGen, Inc. and miRagen Therapeutics Announce Award of National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease

HAMDEN, Conn. & BOULDER, Colo.--(BUSINESS WIRE)--RxGen, a specialty preclinical contract research organization, and miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the award of a Small Business Innovation Research (SBIR) grant by the National Heart Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), of approximately $720,000. These funds will support continued preclinical research on microRNA targeting in cardiovascular disease and help to establish a novel model system of chronic heart failure.